Boston University Medical School Releases Low-UVC/Covid-19 Inactivation Results for the halō

The study, conducted by Dr. Anthony Griffiths at Boston University, validates the performance of LUV Systems’ patent-pending technology at UVC doses below 5 mJ/cm², supporting the effectiveness of its approach to rapid airborne viral inactivation. These findings represent a significant milestone in advancing the company’s low-UVC platform toward commercial deployment.

The halō Model 5R/M, the first in LUV Systems’ portfolio of disinfection products, integrates a fan and proprietary LUV™ light ring to capture air from the breathing zone, disinfect it using controlled UVC exposure, and recirculate cleaned air back into occupied spaces.  Ultraviolet disinfection has been used for more than a century in healthcare, laboratory, and water treatment applications, reinforcing its established efficacy and market acceptance.

Anu Sood, Chief Executive Officer of LUV Systems, commented: “These results from Boston University confirm our core design assumptions and demonstrate rapid viral inactivation performance at low UVC doses. This validation is a key step toward commercialization and reinforces the potential of our technology to address large and growing markets in indoor air quality and infection control.”

The company is continuing its collaboration with Boston University to complete final data validation and expand testing across additional low-UVC wavelengths, including 207, 222, 235, and 245 nanometers, as well as further real-world surface exposure studies.

Danish Khatri, Principal Engineer at LUV Systems, added: “We are encouraged that independent laboratory results align with our theoretical models. Ongoing testing will further refine system performance and support product optimization as we move toward market readiness.”

Neeraj Chaudhary, Business Analyst at LUV Systems, highlighted the broader commercial opportunity: “Our solutions are designed to deliver affordable, effective disinfection across residential, commercial, healthcare, education, retail, entertainment, and transportation sectors, addressing long-term demand for improved indoor air quality.”

LUV Systems continues to make progress across key milestones, including patent filings, laboratory validation, prototype testing, dose modeling, and manufacturing sourcing. The company has also developed a proprietary dosing algorithm that correlates surface viral inactivation data with effective indoor air disinfection rates, enabling predictable and scalable performance across diverse applications.

LUV Systems’ product strategy is built around three core value drivers:

• Proven Effectiveness against a broad range of airborne and surface pathogens;
• Engineered Safety for use in occupied environments, including around people and pets; and
• Affordability to enable widespread adoption across consumer and commercial markets.

With third-party validation from a leading biosafety laboratory, LUV Systems is advancing its low-UVC technology platform toward commercialization across large and diversified global markets.  For example, results have been used by LUV Systems to develop a proprietary dosing algorithm that correlates surface inactivation results with effective air disinfection rates.